ZYME — Recent News Coverage
All news mentioning ZYME in ESEN's AI-graded feed
News stories with ZYME as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on ZYME. See /coverage/ZYME for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-07-01
NEUTRAL
NEUTRAL
CORR0.35
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME)
$ZYME
◈ ESEN AI
Zymeworks (ZYME) has completed a $929 million acquisition of Theravance Biopharma, a strategic deal centered on securing long-term royalty streams from the respiratory therapy asset Yupelri through 2039. This transactio…
SEEKINGALPHA.COM
·
2026-06-30
NEUTRAL
NEUTRAL
CORR0.35
Zymeworks Inc. (ZYME) M&A Call - Slideshow (NASDAQ:ZYME) 2026-06-30
$ZYME
◈ ESEN AI
ZYME published an M&A-focused slideshow presentation on June 30, 2026, signaling management's intent to communicate strategic positioning to investors and potential acquirers. The disclosure of acquisition materials wit…
SEEKINGALPHA.COM
·
2026-06-29
HIGH
NEUTRAL
CORR0.42
Zymeworks Inc. (ZYME) M&A Call Transcript
$ZYME
◈ ESEN AI
Zymeworks Inc. (ZYME) held an M&A call on June 29, 2026, indicating active engagement with strategic transaction processes. M&A announcements at this stage typically signal either defensive positioning, portfolio optimi…
SEEKINGALPHA
·
2026-06-29
NEUTRAL
NEUTRAL
CORR0.15
Zymeworks to pay $17/share for Theravance Biopharma in $929M deal
$TYM
$ZYME
◈ ESEN AI
ZymeworksTheravance Biopharma at $17 per share represents a consolidation move within the biopharmaceutical sector. The $929 million transaction signals strategic portfolio expansion rather than a transformative market …
RTTNEWS.COM
·
2026-06-29
NEUTRAL
NEUTRAL
CORR0.15
Zymeworks To Acquire Theravance Biopharma For $929 Mln In Cash Deal, TBPH Stock Down In Pre-Market
$TBPH
$ZYME
◈ ESEN AI
Zymeworks announced an acquisition of Theravance Biopharma for $929 million in an all-cash transaction at $17.00 per share. This represents a consolidation move within the biopharma sector, where smaller therapeutic dev…
MANILATIMES.NET
·
2026-06-29
HIGH
BULLISH
CORR0.72
Zymeworks to Acquire Theravance Biopharma, Inc.
$TBPH
$ZYME
◈ ESEN AI
Zymeworks announced an acquisition of Theravance Biopharma at $17 per share, representing a significant M&A event in the biopharmaceutical space. The transaction is structured through innovative non-recourse financing, …
GLOBALNEWSWIRE
·
2026-06-29
HIGH
BULLISH
CORR0.72
Zymeworks to Acquire Theravance Biopharma, Inc.
$ZYME
$TBPH
◈ ESEN AI
Zymeworks (ZYME) announced a definitive acquisition of Theravance Biopharma (TBPH), combining two established biotech players in a strategic consolidation. This M&A transaction adds YUPELRI®, an FDA-approved COPD therap…
MANILATIMES.NET
·
2026-06-14
HIGH
BULLISH
CORR0.72
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
$ZYME
◈ ESEN AI
Zymeworks (ZYME) released Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate (ADC), demonstrating substantial clinical efficacy in platinum-resistant ovarian cancer. The compound achieved …
EXPLORE OTHER FILTERS